Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter

USV launches Q rite tablets for treatment of rare aprhythmia in heart patients

Quinidine Sulphate helps manage rare irregular heartbeat conditions

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024

New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control

More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90

Cardiological Society of India releases first Indian guidelines for dyslipidemia management

Dyslipidemia is a critical risk factor for cardiovascular diseases

Modular ATP study of the mCRM System meets primary safety and efficacy endpoints

Additional data from APPRAISE ATP trial reinforce modular therapy approach